Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has been effective diligently but unsuccessfully to create an one off therapy, variously named Pro 140, leronlimab, as well as Vyrologix.

In development of this particular therapy, CytoDyn has cast its net far and wide both geographically and in phrases of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll actually be used is an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as being a combination therapy in the curing of multi-drug-resistant HIV are actually closing.

I am writing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of my last few shares. The first CytoDyn post of mine, “CytoDyn: What In order to Do When It’s Too Good To Be True?”, set away the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan presented such a very promotional picture in the Uptick Newswire employment interview which I came away with a poor impression of the business.

Irony of irony, the poor impression of mine of the company has grown steadily, although the disappointment has not been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger yet still disappoints? Therein sits the story; allow me to explain.

CytoDyn acquired its much-storied therapy (which I shall refer to as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor of the treatment as well as avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti-viral activity in HIV infected subjects. Today’s payment of $3.5 million transfers ownership of the know-how and connected intellectual property coming from Progenics to CytoDyn, and roughly 25 million mg of bulk drug substance…. milestone payments after commencement of a stage III clinical trial ($1.5 million) plus the very first brand new drug program approval ($5 million), and also royalty payments of 5 % of net sales after commercialization.

Since that point in time, CytoDyn’s leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to buy a market place cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous indications and multiple therapies, it’s this individual therapy as well as a “broad pipeline of indications” as it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely beneficial therapy of dozens of indications.

Its opening banner on the site of its (below) shows an energetic business with diverse interests albeit focused on leronlimab, multiple illness types, multiple presentations in addition to multiple publications.

Could all this be smoke and mirrors? That’s a question I have been asking myself through the very beginning of my interest in this business. Judging with the multiples of thousands of diverse responses on listings accessible via Seeking Alpha’s CytoDyn Summary page, I’m much from alone in this question.

CytoDyn is a classic battleground, or maybe some may say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label some negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *